Want to see BVS full AI Analyst Report?
BVS Stock Chart & Stats
$11.80
$0.32(2.79%)
At close: 4:00 PM EDT
$11.80
$0.32(2.79%)
Day’s Range― - ―
52-Week Range$6.26 - $15.89
Previous CloseN/A
Volume472.86K
Average Volume (3M)654.88K
Market Cap
$1.21B
Enterprise Value$976.20
Total Cash (Recent Filing)$29.46M
Total Debt (Recent Filing)$263.75M
Price to Earnings (P/E)17.9
Beta0.73
Next Earnings
Nov 10, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.80
Shares Outstanding68,305,145
10 Day Avg. Volume553,877
30 Day Avg. Volume654,875
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.69
Price to Sales (P/S)0.87
P/FCF Ratio6.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.33Price Target Upside55.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.78
Revenue Forecast (FY)$605.04M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow ConversionBioventus converts reported earnings into cash effectively: operating cash flow rose to ~$105.8M TTM and free cash flow tracked net income at ~0.98x. Durable cash conversion strengthens liquidity, funds organic investment, supports deleveraging and reduces refinancing risk over the medium term.
Deleveraging And Balance Sheet ImprovementManagement has materially reduced debt and signaled a clear path to sub‑1.5x net leverage, while equity rose to ~$228M and TTM debt declined from prior peaks. Sustained deleveraging improves financial flexibility, lowers interest exposure and enhances capacity to invest in growth initiatives over the next several quarters.
Momentum In Pain Treatments & Scalable Growth DriversPain Treatments (Durolane/HA) delivered double‑digit growth and strategic platforms (PRP, PNS, Ultrasonics) are showing accelerating placements and recurring disposables. These drivers combine recurring revenue characteristics with capital plus consumable models, offering durable expansion potential if adoption trends persist.
Bears Say
Uneven Revenue History And VisibilityRevenue growth has been inconsistent: annual revenue was essentially flat in 2025 and prior years included sharp profitability drawdowns. That uneven top‑line history reduces medium‑term visibility and raises execution risk for sustaining margins and cash generation through cyclical or competitive pressures.
Strategic Review Introduces Ownership UncertaintyThe board's strategic‑alternatives review following acquisition interest is a structural governance event that can change long‑term ownership or strategy. Potential outcomes may disrupt continuity of execution, delay investments, or affect customer and employee confidence while the process runs, affecting multi‑quarter plans.
Margin Pressure And Higher Operating InvestmentA ~90bp gross‑margin drag from freight and product mix, coupled with $4M higher operating/R&D spend, tightens near‑term profitability. If elevated investment or adverse mix persists, margin compression could limit further free cash flow growth and slow the company's ability to accelerate deleveraging and fund expansion.
Bioventus News
BVS FAQ
What was Bioventus, Inc.’s price range in the past 12 months?
Bioventus, Inc. lowest stock price was $6.25 and its highest was $15.89 in the past 12 months.
What is Bioventus, Inc.’s market cap?
Bioventus, Inc.’s market cap is $1.21B.
When is Bioventus, Inc.’s upcoming earnings report date?
Bioventus, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 80 days.
How were Bioventus, Inc.’s earnings last quarter?
Bioventus, Inc. released its earnings results on Aug 05, 2026. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.216 by $0.004.
Is Bioventus, Inc. overvalued?
According to Wall Street analysts Bioventus, Inc.’s price is currently Undervalued.
Does Bioventus, Inc. pay dividends?
Bioventus, Inc. does not currently pay dividends.
What is Bioventus, Inc.’s EPS estimate?
Bioventus, Inc.’s EPS estimate is 0.16.
How many shares outstanding does Bioventus, Inc. have?
Bioventus, Inc. has 68,305,145 shares outstanding.
What happened to Bioventus, Inc.’s price movement after its last earnings report?
Bioventus, Inc. reported an EPS of $0.22 in its last earnings report, beating expectations of $0.216. Following the earnings report the stock price went up 13.711%.
Which hedge fund is a major shareholder of Bioventus, Inc.?
Currently, no hedge funds are holding shares in BVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.33 (55.37% Upside)
$18.33 (55.37% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 266.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.73%
Trailing 12-Months
Company Description
Bioventus, Inc.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
BVS Company Deck
BVS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive operational and financial momentum: solid top-line growth (+4% company-wide; +12% in Pain Treatments), margin expansion, strong cash generation and meaningful deleveraging, plus accelerating evidence of traction in strategic growth drivers (PRP, PNS, Ultrasonics, International). Near-term headwinds are mostly transitory and include timing-related revenue shifts (~$2M), modest declines in Surgical, Restorative and International segments, a ~90 bp gross margin drag, higher operating investment and an elevated effective tax rate. Management reaffirmed full-year guidance and expects H2 revenue and cash-flow acceleration, but the announced strategic review introduces a degree of uncertainty. Overall, the positives (durable revenue drivers, profitability, cash generation, deleveraging and confirmed guidance) outweigh the contained near-term challenges.View all BVS earnings summariesBVS Stock 12 Month Forecast
Average Price Target
$18.33
▲(55.37% Upside)
Technical Analysis
Ownership Overview
31.86% Insiders
8.64% Mutual Funds
47.98% Other Institutional Investors
0.05% Public Companies and
Individual Investors